This is a demo store. No orders will be fulfilled.

Depatuxizumab mafodotin (anti-EGFR) - Primary antibody, specific to EGFR, Human IgG1, BINDING AGENT of Epidermal growth factor receptor erbB1 binding agent, BINDING AGENT of Epidermal growth factor receptor erbB1 binding agent

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Mc-MMAF
In stock
Item Number
Ab175508
Grouped product items
SKU Size
Availability
Price Qty
Ab175508-100μg
100μg
10
$199.90
Ab175508-1mg
1mg
4
$919.90
Ab175508-5mg
5mg
1
$2,299.90
Ab175508-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$3,679.90

Purity>95% ( SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (Mc-MMAF)

Basic Description

Product Name Depatuxizumab mafodotin (anti-EGFR) - Primary antibody, specific to EGFR, Human IgG1, BINDING AGENT of Epidermal growth factor receptor erbB1 binding agent
Synonyms Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody | Cell growth inhibiting protein 40 antibody | Cell proliferation inducing protein 61 antibody | EGF R antibody | EGFR antibody | EGFR_HUMAN antibody | Epidermal growth factor recepto
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity EGFR
Conjugation Mc-MMAF
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type BINDING AGENT
Mechanism of action BINDING AGENT of Epidermal growth factor receptor erbB1 binding agent
Product Description

Depatuxizumab mafodotin (anti-EGFR) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab mafodotin (anti-EGFR) is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.7 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 188.1 kDa, under non-reducing conditions.
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1585973-65-4

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin MER intracellular domain/EGFR extracellular domain chimera (2 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin Protein cereblon/Epidermal growth factor receptor (191 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin EGFR/PPP1CA (1 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin VHL/EGFR (323 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - Flow Cytometry
Flow Cytometry analysis of A431 cells labelling EGFR (red) with Depatuxizumab mafodotin (anti-EGFR) (Ab175508). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - ELISA
Immobilized EGFR-chis at 2 μg/mL can bind Depatuxizumab mafodotin (anti-EGFR) (Ab175508) with the EC₅₀ of 19.05 ng/mL.

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - Flow Cytometry
Flow Cytometry analysis of Hela cells labelling EGFR (red) with Depatuxizumab mafodotin (anti-EGFR) (Ab175508). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - Flow Cytometry
Flow Cytometry analysis of A549 cells labelling EGFR (red) with Depatuxizumab mafodotin (anti-EGFR) (Ab175508). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - SEC
The purity of Depatuxizumab mafodotin (anti-EGFR) (Ab175508) is more than 95% verified by HPLC.

Depatuxizumab mafodotin (anti-EGFR) (Ab175508) - ELISA
Immobilized Recombinant Human EGFR protein (rp176273) at 1.0 μg/mL can bind Depatuxizumab mafodotin (anti-EGFR) (Ab175508) with the EC50 of 28.96 ng/mL.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0102634 Certificate of Analysis Jan 26, 2024 Ab175508
ZJ24F0102635 Certificate of Analysis Jan 26, 2024 Ab175508
ZJ24F0102636 Certificate of Analysis Jan 26, 2024 Ab175508

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.